Sign in to continue:

Tuesday, March 24th, 2026

Day: March 18, 2026

Incannex Highlights $75 Million Cash, No Debt, and Advances IHL-42X and PSX-001 Clinical Programs

Incannex Healthcare Highlights Strong Financial Position and...

Cingulate Reports 2025 Financial Results, Advances CTx-1301 ADHD Drug with New Patents and NDA Progress

Cingulate Inc. Reports Q4 and Full Year 2025 Results: Key Hi...

GSI Technology Concludes Strategic Alternatives Review and Reaffirms Standalone Growth Strategy

GSI Technology Announces Conclusion of Strategic Alternative...